Kauffman Michael 4

4 · Adicet Bio, Inc. · Filed Aug 23, 2024

Form 4

Period: 2024-08-21

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2024-08-21−37,000→ 0 total
Exercise: $2.14Exp: 2031-11-16→ Common Stock (37,000 underlying)
Award
Stock Option (Right to Buy)
2024-08-21+37,000→ 37,000 total
Exercise: $9.39Exp: 2031-11-16→ Common Stock (37,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2024-08-21−18,500→ 0 total
Exercise: $2.14Exp: 2032-06-01→ Common Stock (18,500 underlying)
Award
Stock Option (Right to Buy)
2024-08-21+18,500→ 18,500 total
Exercise: $11.49Exp: 2032-06-01→ Common Stock (18,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2024-08-21−26,400→ 0 total
Exercise: $2.14Exp: 2033-05-31→ Common Stock (26,400 underlying)
Award
Stock Option (Right to Buy)
2024-08-21+26,400→ 26,400 total
Exercise: $5.20Exp: 2033-05-31→ Common Stock (26,400 underlying)

Footnotes (3)

[F1]Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
[F2]The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
[F3]The shares subject to this option are fully vested and exercisable as of the date hereof.

Documents

1 file